Artificial Intelligence
Computational Biology Market Size & Share to Surpass $ 10.82 Billion by 2028 | Vantage Market Research
<!– Name:DistributionId Value:8805427 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1235589 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:ca28e992-0f2b-41a3-aa11-ecc0e02f157a –>
WASHINGTON, April 11, 2023 (GLOBE NEWSWIRE) — The Global Computational Biology Market is valued at USD 4.71 Billion in 2022 and is projected to attain a value of USD 17.46 Billion by 2030 at a CAGR of 17.80% during the forecast period, 2023–2030.
Market Overview
The growth of the market is attributed to the increasing demand for computational biology in drug discovery and development, personalized medicine, and precision medicine.
Computational biology is a branch of biology that uses computer science and mathematics to study biological systems. It is used to model and simulate biological processes, identify patterns in biological data, and develop new drugs and therapies.
The drug discovery and development segment is expected to be the largest market for computational biology during the forecast period. The growth of this segment is attributed to the increasing demand for new drugs and therapies for the treatment of chronic diseases. Computational biology is used in drug discovery and development to identify potential drug targets, screen compounds for efficacy and toxicity, and optimize drug candidates.
The personalized medicine segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is attributed to the increasing demand for personalized healthcare. Computational biology is used in personalized medicine to develop tailored treatments for individual patients. It is used to identify genetic variants that may be associated with a disease, and to predict the response of a patient to a particular drug.
The precision medicine segment is expected to grow at a moderate CAGR during the forecast period. The growth of this segment is attributed to the increasing demand for precision medicine. Precision medicine is a type of healthcare that takes into account the individual’s genetic makeup, environment, and lifestyle to develop tailored treatments. Computational biology is used in precision medicine to identify genetic variants that may be associated with a disease, and to predict the response of a patient to a particular drug.
Get Access to Free Sample Research Report with Latest Industry Insights @ https://www.vantagemarketresearch.com/computational-biology-market-1302/request-sample
Market Dynamics
The computational biology market is driven by several factors, including advancements in technology, increasing demand for personalized medicine, and the need for more efficient drug discovery and development processes. However, the market also faces challenges such as data security concerns, lack of standardization, and shortage of skilled professionals.
Advancements in technology, particularly in omics technologies, have led to the generation of large amounts of complex data, which require sophisticated computational tools for analysis and interpretation. This has led to an increasing demand for computational biology tools and services.
The demand for personalized medicine is also driving the growth of the computational biology market. Personalized medicine involves tailoring medical treatment to individual patients based on their genetic makeup and other personal factors. Computational biology tools are essential in identifying biomarkers and developing targeted therapies for specific patient groups.
Efficient drug discovery and development processes are also crucial in the pharmaceutical and biotechnology industry. Computational biology tools are used in drug discovery and development to identify potential drug targets, optimize drug efficacy and safety, and reduce development costs and time.
However, the market also faces challenges such as data security concerns. As the amount of sensitive data generated by omics technologies increases, data security concerns become more significant. Companies and institutions must ensure that they have appropriate measures in place to protect sensitive data.
The lack of standardization is also a challenge in the computational biology market. The lack of standardization in data formats and analysis methods can lead to inconsistencies in research results and hinder collaboration between different research groups.
Finally, there is a shortage of skilled professionals in the computational biology field. The demand for skilled professionals is high, but the supply is limited. This shortage is expected to continue in the coming years, posing a challenge to the growth of the market.
Top Players in the Global Computational Biology Market
- Dassault Systèmes SE (France)
- Chemical Computing Group ULC (Canada)
- Genedata AG (Switzerland)
- Instem PLC (UK)
- Compugen Ltd (Israel)
Budget Limitation? Contact us for Special Discount and Pricing
Top Report Findings
- The computational biology market is expected to grow at a compound annual growth rate (CAGR) of 17.80 from 2023 to 2030.
- The drug discovery and development segment are expected to be the largest market for computational biology during the forecast period.
- The personalized medicine segment is expected to grow at the highest CAGR during the forecast period.
- The growth of the computational biology market is being driven by the increasing demand for computational biology in drug discovery and development, personalized medicine, and precision medicine.
- The key challenges that are hindering the growth of the computational biology market are lack of skilled professionals in computational biology, high cost of computational biology tools and software, complex regulatory landscape, and data privacy and security concerns.
The computational biology market is segmented on the basis of application, end-user, and region. Based on application, the market is segmented into drug discovery and development, personalized medicine, precision medicine, and others. The drug discovery and development segment is expected to be the largest market for computational biology during the forecast period. This is attributed to the increasing demand for new drugs and therapies for the treatment of chronic diseases. Computational biology is used in drug discovery and development to identify potential drug targets, screen compounds for efficacy and toxicity, and optimize drug candidates.
Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and government organizations. The pharmaceutical and biotechnology companies’ segment is expected to be the largest market for computational biology during the forecast period. This is attributed to the increasing investment by pharmaceutical and biotechnology companies in R&D activities to develop new drugs and therapies. Computational biology is used by pharmaceutical and biotechnology companies to identify potential drug targets, screen compounds for efficacy and toxicity, and optimize drug candidates.
Based on region, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to be the largest market for computational biology during the forecast period. This is attributed to the presence of a large number of pharmaceutical and biotechnology companies in the region. Additionally, the region is also home to a number of academic and research institutes that are involved in computational biology research.
Top Trends in Global Computational Biology Market
- Cloud Computing and Big Data Analytics: The increasing amount of data generated by omics technologies requires sophisticated computational tools for analysis and interpretation. Cloud computing provides a scalable and cost-effective solution for managing large amounts of data and enables researchers to access computational resources from anywhere in the world. Big data analytics, on the other hand, involves using advanced algorithms and statistical techniques to extract insights from complex data sets.
- Integration of Artificial Intelligence and Machine Learning: Artificial intelligence (AI) and machine learning (ML) are increasingly being integrated into computational biology to improve the accuracy and efficiency of data analysis and interpretation. AI and ML algorithms can help identify patterns in large data sets, predict outcomes, and optimize drug discovery and development processes.
- Single-Cell Analysis Technologies: Single-cell analysis technologies are emerging as a key trend in the computational biology market. These technologies enable researchers to analyze individual cells and uncover insights into cellular heterogeneity, cellular function, and disease mechanisms. Single-cell analysis technologies are particularly useful in cancer research and personalized medicine.
- Collaborative Research Initiatives: Collaborative research initiatives are becoming more prevalent in the computational biology market. These initiatives involve multiple organizations, such as academic institutions, research organizations, and pharmaceutical companies, working together to solve complex research problems. Collaborative research initiatives enable researchers to access expertise, share data, and pool resources, leading to faster and more efficient research outcomes.
- Open-Source Software: Open-source software is becoming increasingly popular in the computational biology market. Open-source software allows researchers to access and modify software code, enabling them to customize software tools to their specific research needs. Open-source software also promotes collaboration and knowledge sharing within the research community.
Buy this Premium Research Report with Discount | Immediate Delivery @ https://www.vantagemarketresearch.com/buy-now/computational-biology-market-1302/0
Regional Analysis
- North America: North America is the largest market for computational biology, owing to the presence of a large number of pharmaceutical and biotechnology companies, research organizations, and academic institutions in the region. The United States dominates the North American market, with Canada also contributing significantly to the growth of the market in the region. The increasing demand for personalized medicine, the need for more efficient drug discovery and development processes, and the growing adoption of advanced technologies are driving the growth of the computational biology market in North America.
- Europe: Europe is the second-largest market for computational biology, driven by the increasing investment in research and development activities, the presence of a large patient population, and the growing demand for personalized medicine. The United Kingdom, Germany, France, and Italy are the major contributors to the growth of the computational biology market in Europe.
- Asia-Pacific: The Asia-Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the increasing investment in research and development activities, the presence of a large patient population, and the growing demand for personalized medicine. China, Japan, and India are the major contributors to the growth of the computational biology market in the Asia-Pacific region.
- Latin America: The Latin American market for computational biology is expected to grow significantly during the forecast period, driven by the increasing investment in research and development activities, the growing adoption of advanced technologies, and the presence of a large patient population. Brazil, Mexico, and Argentina are the major contributors to the growth of the computational biology market in Latin America.
- Middle East and Africa: The Middle East and Africa region is expected to show moderate growth during the forecast period, driven by the increasing investment in research and development activities, the growing adoption of advanced technologies, and the presence of a large patient population. Saudi Arabia, the United Arab Emirates, and South Africa are the major contributors to the growth of the computational biology market in the Middle East and Africa
Browse market data Tables and Figures spread through 158 Pages and in-depth TOC on Computational Biology Market Forecast Report (2023-2030).
Global Computational Biology Market Segmentation
By Application
- Cellular & Biological Simulation
- Drug Discovery & Disease Modelling
- Preclinical Drug Development
- Clinical Trials
- Human Body Simulation Software
By Services
- n-house
- Contract
By End-Use
- Academics
- Industry
- Commercial
By Region
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-East Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of MEA
Read Full Report with TOC @ https://www.vantagemarketresearch.com/industry-report/computational-biology-market-1302
Scope of the Report:
| Report Attributes | Details |
| Market Size in 2022 | USD 4.71 Billion |
| Revenue Forecast by 2030 | USD 17.46 Billion |
| CAGR | 17.80% from 2023 to 2030 |
| Base Year | 2022 |
| Forecast Year | 2023 to 2030 |
| Key Players | Chemical Computing Group Inc.; Compugen Ltd.; Simulation Plus Inc.; Genedata AG; Certara; Insilico Biotechnology AG; Accelrys; Rhenovia Pharma SAS; Entelos; Nimbus Discovery LLC; and Rhenovia Pharma SAS. |
| Customization Options | If our report does not include the information you are searching for, you may contact us to have a report tailored to your specific business needs https://www.vantagemarketresearch.com/computational-biology-market-1302/request-sample |
The key questions answered in the Computational Biology Market Report are:
- What is the size and potential of the global computational biology market, and what are its growth prospects during the forecast period?
- What are the key drivers, challenges, and opportunities in the computational biology market, and how are they expected to impact market growth?
- What are the major applications of computational biology, and what is the current and projected market share of each application?
- What are the major end-users of computational biology, and what is the current and projected market share of each end-user?
- What are the major technologies used in computational biology, and what is the current and projected market share of each technology?
- What are the major products and services offered in the computational biology market, and what is the current and projected market share of each product and service?
- What are the major geographic regions in the computational biology market, and what is the current and projected market share of each region?
- Who are the major players in the computational biology market, and what are their market strategies, competitive landscape, and recent developments?
- What are the major trends in the computational biology market, and how are they expected to shape the market during the forecast period?
- What are the major challenges faced by the computational biology market, and what are the strategies adopted by companies to overcome these challenges?
The report also provides a detailed analysis of the competitive landscape of the computational biology market, and profiles of the key players involved in the market. The report also provides a comprehensive analysis of the market dynamics, including drivers, restraints, opportunities, and challenges.
Browse More Reports from Vantage Library:
About Vantage Market Research:
We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies.
Follow Us on: LinkedIn | Twitter | Facebook | YouTube
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 – 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: [email protected]
Website: https://www.vantagemarketresearch.com/
Latest Vantage Market Research Press Releases
Latest Vantage Market Research Blog
Vantage Market Research All Reports
Blog:
Artificial Intelligence
J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit
In conjunction with Abu Dhabi Global Healthcare Week 2024
ABU DHABI, UAE, May 17, 2024 /PRNewswire/ — J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group announced today Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.
In partnership with the Department of Health – Abu Dhabi (DoH), the Summit took place on May 14-15, 2024 at Cleveland Clinic Abu Dhabi and showcased the 11 innovative finalists, as well as highlighted existing innovators and opportunities in the Emirate of Abu Dhabi. The event also featured keynote speeches from Dr. Laurie Glimcher of Dana-Farber Cancer Institute, Dr. Shahrukh Hashmi of the Department of Health – Abu Dhabi, and Dr. David Ho of Columbia University Medical Center and provided attendees networking opportunities to gain valuable insights into the future of life sciences innovation.
In addition, the jury designated Chun-Hao Huang of Algen Biotechnologies as honourable mention. Algen Biotechnologies is a platform therapeutics and drug discovery company using world-leading CRISPR and AI to find treatments for cancer, inflammation and metabolic diseases.
The winners were selected by an esteemed, international panel of judges, which included:Laurie Glimcher, MD, President and CEO at Dana-Farber Cancer InstituteJorge Guzman, MD, CEO at Cleveland Clinic Abu DhabiProf. Shahrukh Khurshid Hashmi, MD, Director of Research, Department of Health, Abu DhabiYasmine Hayek Kobeissi, PhD, CQF, BSc., Executive Director at Blue Horizon AdvisorsAnya Schiess, Managing Partner at J.P. Morgan Life Sciences Private CapitalWalid Zaher, PhD, Co-Founder and CEO, Carexso
Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi said: “Under the directives of the UAE’s wise leadership, and renowned for its world-leading medical infrastructure, Abu Dhabi stands at the forefront of healthcare excellence, offering an unparalleled opportunity for advancement in healthcare for global partners. It was our utmost pleasure hosting the J.P. Morgan Asset Management Life Sciences Innovation Summit 2024 on the sidelines of Abu Dhabi Global Healthcare Week and we commend the winners for their pioneering efforts in driving impactful advancements in healthcare; their dedication to innovation not only transforms the landscape of medicine, but also holds the promise of improving lives worldwide.”
Stephen Squinto, PhD, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital said: “We are thrilled with the level of biotech passion and innovation that we observed at this year’s Summit in Abu Dhabi. The energy was truly palpable we are thrilled to announce Rayees Rahman as the winner of our first Life Sciences Innovation Summit. Harmonic Discovery’s approach embodies the next generation of drug discovery and development. We appreciate the time and effort of all participants and cannot wait for our next event in the region.”
Nabil Kobeissi, Chief Executive Officer of Blue Horizon Advisors, said: “As the main sponsor, we are committed to nurturing and fostering the growth of all 11 finalists in this vibrant biotech ecosystem. This Summit marks the beginning of a transformative journey, and we are confident that it will pave the way for a flourishing hub in the region. We are also pleased to announce that we will commit to invest in and partner with the winner, Harmonic Discovery, to support its future growth in the region.”
Sponsors for the event included J.P. Morgan Life Sciences Private Capital, J.P. Morgan Commercial Bank, Blue Horizon Advisors, United Al Saqer Group, Thermo Fisher Scientific, and Salam Capital. The Summit organisation, logistics and finalist recruitment were facilitated by Lyfebulb.
Of importance, at the Summit, Mr. Mohamed Al Breiki, Executive Director of Sustainable Development at Masdar City, announced that Masdar City Free Zone would award all 11 Finalists complimentary business licenses to further support their establishment in the region. Masdar City is one of the world’s most sustainable urban developments and innovation hubs with a growing focus on life science entrepreneurship in Abu Dhabi.
View original content:https://www.prnewswire.co.uk/news-releases/jp-morgan-life-sciences-private-capital-blue-horizon-advisors-and-united-al-saqer-announce-winner-of-inaugural-2024-life-sciences-innovation-summit-302149186.html
Artificial Intelligence
Congregating in the Lion City for a Win-Win Future of Intelligent Computing at the Global Data Center Facility Summit 2024
SINGAPORE, May 17, 2024 /PRNewswire/ — On May 17, 2024, the Global Data Center Facility Summit 2024 was held in Singapore with the theme of “Power the Digital Era Forward.” At the summit, over 600 data center industry leaders, technical experts, and ecosystem partners gathered to discuss new trends and opportunities of the global data center industry in the intelligent computing era. The attendees also got to experience all-scenario, all-ecosystem, and all-service end-to-end (E2E) solutions, share innovative practices of green data centers in the Asia Pacific and Europe, and experience the exhibition vehicle to unveil the mystery of Outdoor PowerPOD that features one power system per container. By fully embracing the intelligent computing era, Huawei strives to power the digital era forward.
Seizing Opportunities Brought by AI and Jointly Building Green & Reliable Computing Infrastructure
At the opening speech, Charles Yang, Senior Vice President of Huawei and President of Marketing, Sales and Services, Huawei Digital Power, noted that since ChatGPT ushered in the AI era, large models keep pushing the limits of computing power and the intelligent computing industry is witnessing an unprecedented construction boom. As predicted, 100 GW will be added to the global data center installed capacity and the market value will exceed US$600 billion in the next five years.
According to Charles, with opportunities come challenges. The primary challenge concerning the data center industry is reliability and electricity. Data centers are scaling up from the MW-level to the GW-level. E2E reliability of data centers is becoming even more important than ever. In response to the opportunities, Huawei will work with customers and partners to expand the industry space.
Steering Data Centers to the AI Era with Product + Service + Ecosystem
During the summit, Sun Xiaofeng, President of Huawei Data Center Facility & Critical Power Business, delivered a speech titled “Power the Digital Era Forward. ” He stated that as AI large models are penetrating, the surging compute demands drive the expansive growth in data center.
To address the challenges, Huawei strives to build product + service + ecosystem E2E data center solutions that feature fast deployment, flexible cooling, green energy, and ultimate reliability.
Fast deployment: Data centers are fully modularized and prefabricated to ensure high quality and efficient construction.Flexible cooling: Air-liquid fusion and integrated cooling source emerges as the optimal cooling architecture for intelligent computing.Green energy: New generation-grid-load-storage integrated solution is built to ensure the sound operations of intelligent computing centers.Ultimate reliability: Data centers are safeguarded through reliable products and preventive protection.Currently, Huawei’s global service network covers more than 170 countries with over 1800 professional engineers, providing 24/7 technical support. With N+ flagship service centers, Huawei has built a one-hour service radius for its customers.
The ecosystem is a key part for a win-win future of intelligent computing. Huawei works with partners to develop comprehensive E2E solutions and provide customers with one-stop data center services.
During the summit, Huawei and the ASEAN Centre for Energy released a white paper on “Building Next Generation Data Center Facility in ASEAN.” The document provides insights into the status quo, challenges, and trends of data centers in the ASEAN region, and emphasizes that efficient and energy-saving products and solutions should be applied. It also proposes future-oriented policy recommendations for data center markets.
In the ecosystem exhibition area, Huawei showcased scenario-based solutions for large-, medium-, and small-sized data centers, and demonstrated data center consulting, design, integrated development, and delivery capabilities with dozens of ecosystem partners including CIMC, Weichai, CSCEC, and Huashi.
On a special note, the Huawei Outdoor PowerPOD exhibition vehicle made its global debut. The Huawei Outdoor PowerPOD features one power system per container, outdoor deployment, plug-and-play, and high protection rating and reliability. It has become the preferred choice for decoupling the power supply architecture.
A single tree cannot make a forest.
AI is presenting great opportunities. By delving into the industry, aggregating partner ecosystems, and making innovations applicable to transformations, Huawei will continue to help customers build reliable computing infrastructure, accelerating the industry to embrace AI and powering the digital era forward.
Photo – https://mma.prnewswire.com/media/2415818/Global_Data_Center_Facility_Summit_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/congregating-in-the-lion-city-for-a-win-win-future-of-intelligent-computing-at-the-global-data-center-facility-summit-2024-302148973.html
Artificial Intelligence
HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market
WASHINGTON D.C., May 17, 2024 /PRNewswire/ — HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced today their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships.
Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.
MAGENTIQ-COLO™ is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies. Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in Europe, United States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.
“We are excited to bring the MAGENTIQ-COLO™ device to the GI community in the U.S. Together with PENTAX Medical’s product portfolio, we are confident to provide a smart solution in colonoscopy and contribute further to colorectal cancer prevention”, says David Harrison, President PENTAX of America, Inc.
“Partnering with PENTAX Medical is an important milestone for us, as it opens new opportunities to introduce our game changing product to the U.S. market, benefiting doctors and their patients and saving more lives”, says Dror Zur, Founder & CEO of MAGENTIQ-EYE.
About MAGENTIQ-EYE Ltd.Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI-aided colonoscopy solution that offers one of the best performances known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives. www.magentiq.com
About PENTAX Medical
PENTAX Medical is a division of HOYA Group. The company’s mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on QUALITY, CLINICALLY RELEVANT INNOVATION, and SIMPLICITY. PENTAX Medical strives to align with the healthcare community’s Triple Aim goals through transparent partnerships with its customers and by providing the highest quality solutions to help them reach their goals, including enabling customers to improve patient outcomes by offering evidence-based solutions across the continuum of care; ensuring value by supporting the customers to improve their efficiency and minimize their healthcare costs; and enriching patient and provider’s experience by empowering every member of the care team to achieve optimal outcomes through products, education, and support. Focused on the outcome instead of technological features, PENTAX Medical listens to the healthcare community and their patients, understands their daily obstacles and helps improve endoscopy with smart innovations.
For more information: https://www.pentaxmedical.com
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA is active in the fields of lifecare and information technology, providing eyeglasses, medical endoscopes, intraocular lenses, optical lenses, as well as key components for semiconductor devices, LCD panels, and hard disk drives. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 36,000 people. For more information, please visit: https://www.hoya.com/en/
View original content:https://www.prnewswire.co.uk/news-releases/hoya-group-company-pentax-of-america-inc-and-magentiq-eye-ltd-announce-their-intention-to-form-a-distribution-partnership-for-the-us-market-302148971.html
-
Artificial Intelligence7 days agoWIO Taps Gracenote to Revolutionize Television Broadcast Reporting
-
Uncategorized4 days agoCrossover Markets Becomes First Crypto ECN to Integrate with Talos
-
Artificial Intelligence4 days agoAdvanced HPC Server Platforms by MiTAC and TYAN Spotlighted at ISC High Performance 2024
-
Uncategorized4 days ago
Precisely Showcases Critical Role of Trusted Data in AI at the Gartner® Data & Analytics Summit in London
-
Uncategorized3 days ago
Artificial intelligence tool detects sex-related differences in brain structure
-
Artificial Intelligence5 days agoMSI Highlights Optimized AI Platforms to Accelerate Compute-Intensive Applications at ISC 2024
-
Artificial Intelligence6 days agoElevate Your Virtual Reality Experience with KIWI design RGB Vertical Stand, Now Available on Meta’s Website
-
Artificial Intelligence5 days ago
Supermicro’s Rack Scale Liquid-Cooled Solutions with the Industry’s Latest Accelerators Target AI and HPC Convergence
